# Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

> **NCT05354349** · PHASE1 · COMPLETED · sponsor: **Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 49 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PRA023 IV Low Dose
- **DRUG:** PRA023 SC
- **DRUG:** Placebo IV
- **DRUG:** Placebo SC
- **DRUG:** PRA023 IV High Dose

## Key facts

- **NCT ID:** NCT05354349
- **Lead sponsor:** Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-06
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-01-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05354349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05354349, "Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05354349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*